数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael Ackermann Chairperson of the Board 38 10.00万(USD) 未持股 2020-09-30
Bobak Azamian President, Chief Executive Officer and Director 42 41.61万(USD) 未持股 2020-09-30
Andrew Goldberg Director 39 未披露 未持股 2020-09-30
Jason Tester Director 44 未披露 未持股 2020-09-30
William J. Link Director 74 未披露 未持股 2020-09-30
Bhaskar Chaudhuri Director 66 未披露 未持股 2020-09-30

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Bobak Azamian President, Chief Executive Officer and Director 42 41.61万(USD) 未持股 2020-09-30
Seshadri Neervannan Chief Operating Officer 52 未披露 未持股 2020-09-30
Aziz Mottiwala Chief Commercial Officer 43 未披露 未持股 2020-09-30
Mark Holdbrook Vice President, Clinical Affairs 67 30.82万(USD) 未持股 2020-09-30
Leo M. Greenstein Chief Financial Officer 44 未披露 未持股 2020-09-30

董事简历

中英对照 |  中文 |  英文
Michael Ackermann
暂无中文简介

Michael Ackermann has served as a member of our board of directors and as chairperson of our board of directors since July 2017. Dr. Ackermann has been the Chief Executive Officer of Presidio Medical, Inc. since September 2017. From October 2017 until October 2020 Mr. Ackermann served as the chairman of the board of Oyster Point Pharma. Prior to that, he was Vice President, Neurostimulation for Allergan from August 2015 to June 2017 after serving as Chief Executive Officer of Oculeve, which was acquired by Allergan, from June 2012 to August 2015. Dr. Ackermann received a B.E. in biomedical engineering from Vanderbilt University and a M.S. and Ph.D. in biomedical engineering from Case Western Reserve University.
暂无中文简介
Michael Ackermann has served as a member of our board of directors and as chairperson of our board of directors since July 2017. Dr. Ackermann has been the Chief Executive Officer of Presidio Medical, Inc. since September 2017. From October 2017 until October 2020 Mr. Ackermann served as the chairman of the board of Oyster Point Pharma. Prior to that, he was Vice President, Neurostimulation for Allergan from August 2015 to June 2017 after serving as Chief Executive Officer of Oculeve, which was acquired by Allergan, from June 2012 to August 2015. Dr. Ackermann received a B.E. in biomedical engineering from Vanderbilt University and a M.S. and Ph.D. in biomedical engineering from Case Western Reserve University.
Bobak Azamian
暂无中文简介

Bobak Azamian is our co-founder and has served as our President since our inception, as our Chief Executive Officer since September 2018 and as a member of our board of directors since December 2016. From June 2012 to September 2018 Dr. Azamian co-founded and served as Chief Executive Officer, President, and Chief Medical Officer of Metavention, Inc., a company focused on treatment of diabetes and other metabolic diseases. Since September 2016 Dr. Azamian has also served as co-founder, co-Chairman and Chief Executive Officer of Vibrato Medical, Inc., a medical device company developing wearable treatments for peripheral arterial disease. Dr. Azamian previously served as an Entrepreneur in Residence at Versant Ventures from 2011 to 2013 and as a consultant and Senior Associate at Third Rock Ventures from 2007 to 2011 both venture capital firms focused on investing in early stage healthcare companies, and earlier served as a consultant at Amgen. He also completed residency in internal medicine and served as an attending hospitalist at Brigham and Women’s Hospital from 2006 to 2011. Dr. Azamian received a B.A. in Biophysics from Rice University, a Doctor of Philosophy Chemistry from University of Oxford and a Doctor of Medicine from Harvard Medical School.
暂无中文简介
Bobak Azamian is our co-founder and has served as our President since our inception, as our Chief Executive Officer since September 2018 and as a member of our board of directors since December 2016. From June 2012 to September 2018 Dr. Azamian co-founded and served as Chief Executive Officer, President, and Chief Medical Officer of Metavention, Inc., a company focused on treatment of diabetes and other metabolic diseases. Since September 2016 Dr. Azamian has also served as co-founder, co-Chairman and Chief Executive Officer of Vibrato Medical, Inc., a medical device company developing wearable treatments for peripheral arterial disease. Dr. Azamian previously served as an Entrepreneur in Residence at Versant Ventures from 2011 to 2013 and as a consultant and Senior Associate at Third Rock Ventures from 2007 to 2011 both venture capital firms focused on investing in early stage healthcare companies, and earlier served as a consultant at Amgen. He also completed residency in internal medicine and served as an attending hospitalist at Brigham and Women’s Hospital from 2006 to 2011. Dr. Azamian received a B.A. in Biophysics from Rice University, a Doctor of Philosophy Chemistry from University of Oxford and a Doctor of Medicine from Harvard Medical School.
Andrew Goldberg
暂无中文简介

Andrew Goldberg has served as a member of our board of directors since August 2020. Since February 2016 Dr. Goldberg has served as a principal of Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry. Prior to this, Dr. Goldberg was a consultant at McKinsey & Company from September 2014 to February 2016 where he served pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg is a U.S. board-certified physician in both Critical Care Medicine and Emergency Medicine. He recently served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, from January 2013 to June 2013 where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. Prior to this, he completed Emergency Medicine residency training at Los Angeles County + University of Southern California Medical Center LAC+USC. His research has spanned a variety of topics, from traumatic brain injury and cardiac arrest to biomarker analysis and healthcare quality. He has over 25 scientific publications in leading peer-reviewed journals, including JAMA, Resuscitation, and the Cleveland Clinic Journal of Medicine. Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post-doctoral diploma in translational science from the Mayo Graduate School. He has held prior academic and clinical appointments at Oregon Health & Science University and the University of Arizona and currently at the Washington Township Medical Foundation.
暂无中文简介
Andrew Goldberg has served as a member of our board of directors since August 2020. Since February 2016 Dr. Goldberg has served as a principal of Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry. Prior to this, Dr. Goldberg was a consultant at McKinsey & Company from September 2014 to February 2016 where he served pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg is a U.S. board-certified physician in both Critical Care Medicine and Emergency Medicine. He recently served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, from January 2013 to June 2013 where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. Prior to this, he completed Emergency Medicine residency training at Los Angeles County + University of Southern California Medical Center LAC+USC. His research has spanned a variety of topics, from traumatic brain injury and cardiac arrest to biomarker analysis and healthcare quality. He has over 25 scientific publications in leading peer-reviewed journals, including JAMA, Resuscitation, and the Cleveland Clinic Journal of Medicine. Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post-doctoral diploma in translational science from the Mayo Graduate School. He has held prior academic and clinical appointments at Oregon Health & Science University and the University of Arizona and currently at the Washington Township Medical Foundation.
Jason Tester
暂无中文简介

Jason Tester has served as a member of our board of directors since March 2018. Since September 2017 Mr. Tester has served as Chief Financial Officer of the Horowitz Group. From September 2008 to August 2017 Mr. Tester was Chief Financial Officer of AcuFocus, an ophthalmic medical device company. From July 2007 to May 2008 Mr. Tester was Vice President of Jefferies & Company, a healthcare investment bank. Mr. Tester holds an MBA in finance from the Emory University Goizueta Business School, a Master of Accountancy with a specialization in taxation and a Bachelor of Business Administration from the University of Georgia.
暂无中文简介
Jason Tester has served as a member of our board of directors since March 2018. Since September 2017 Mr. Tester has served as Chief Financial Officer of the Horowitz Group. From September 2008 to August 2017 Mr. Tester was Chief Financial Officer of AcuFocus, an ophthalmic medical device company. From July 2007 to May 2008 Mr. Tester was Vice President of Jefferies & Company, a healthcare investment bank. Mr. Tester holds an MBA in finance from the Emory University Goizueta Business School, a Master of Accountancy with a specialization in taxation and a Bachelor of Business Administration from the University of Georgia.
William J. Link

William J. Link,他一直担任我们董事会的成员(2003年以来)。他是Versant Ventures公司(风险资本公司,专门从事早期投资医疗公司)的共同创始人兼董事总经理(1999年公司成立以来)。共同创立Versant Ventures公司之前,他曾担任Brentwood Venture Capital公司的普通合伙人(从1998年到现在)。他也曾创立Chiron Vision公司(Chiron Corporation的子公司,专注于眼科手术产品,于1997年出售给Bausch and Lomb公司),并担任主席兼首席执行官(从1986年到1997年)。任职Chiron Vision公司之前,他曾于1978年创立American Medical Optics AMO公司(merican Hospital Supply Corporation的部门,于1986年出售给Allergan公司),并担任总裁。他也曾任职Advanced Medical Optics (AMO公司的前身公司,于2009年被Abbott公司收购)的董事会(从2002年到2009年)。他曾担任印第安纳大学医学院(the Indiana University School of Medicine)外科学系助理教授(从1973年到1976年)。他持有普渡大学(Purdue University)的学士学位、硕士学位和博士学位。


William J. Link has served as a member of our board of directors since January 2017. Dr. Link is a managing director and co-founder of both Flying L Partners, a venture capital firm formed in 2016 to focus on investing primarily in the ophthalmic space, and Versant Venture Management LLC, a life science venture capital firm investing in early stage healthcare companies. Prior to co-founding Versant in 1999 Dr. Link was a general partner at Brentwood Venture Capital. From 1987 to 1997 Dr. Link was founder, chairman, and Chief Executive Officer of Chiron Vision Corporation acquired by Bausch & Lomb. He also founded and served as President of American Medical Optics (acquired by Allergan). Dr. Link served as a director of Advanced Medical Optics (acquired by Abbott) from 2002 to 2009 and Inogen from 2003 to February 2014. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. He has been a member of the board of directors of Edwards Lifesciences Corporation since May 2009 Second Sight Medical Products from 2003 to May 31 2020 Glaukos Corporation since 2001 and Oyster Point Pharma since July 2015. Dr. Link holds a B.S., an M.S., and a Ph.D. in mechanical engineering from Purdue University.
William J. Link,他一直担任我们董事会的成员(2003年以来)。他是Versant Ventures公司(风险资本公司,专门从事早期投资医疗公司)的共同创始人兼董事总经理(1999年公司成立以来)。共同创立Versant Ventures公司之前,他曾担任Brentwood Venture Capital公司的普通合伙人(从1998年到现在)。他也曾创立Chiron Vision公司(Chiron Corporation的子公司,专注于眼科手术产品,于1997年出售给Bausch and Lomb公司),并担任主席兼首席执行官(从1986年到1997年)。任职Chiron Vision公司之前,他曾于1978年创立American Medical Optics AMO公司(merican Hospital Supply Corporation的部门,于1986年出售给Allergan公司),并担任总裁。他也曾任职Advanced Medical Optics (AMO公司的前身公司,于2009年被Abbott公司收购)的董事会(从2002年到2009年)。他曾担任印第安纳大学医学院(the Indiana University School of Medicine)外科学系助理教授(从1973年到1976年)。他持有普渡大学(Purdue University)的学士学位、硕士学位和博士学位。
William J. Link has served as a member of our board of directors since January 2017. Dr. Link is a managing director and co-founder of both Flying L Partners, a venture capital firm formed in 2016 to focus on investing primarily in the ophthalmic space, and Versant Venture Management LLC, a life science venture capital firm investing in early stage healthcare companies. Prior to co-founding Versant in 1999 Dr. Link was a general partner at Brentwood Venture Capital. From 1987 to 1997 Dr. Link was founder, chairman, and Chief Executive Officer of Chiron Vision Corporation acquired by Bausch & Lomb. He also founded and served as President of American Medical Optics (acquired by Allergan). Dr. Link served as a director of Advanced Medical Optics (acquired by Abbott) from 2002 to 2009 and Inogen from 2003 to February 2014. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. He has been a member of the board of directors of Edwards Lifesciences Corporation since May 2009 Second Sight Medical Products from 2003 to May 31 2020 Glaukos Corporation since 2001 and Oyster Point Pharma since July 2015. Dr. Link holds a B.S., an M.S., and a Ph.D. in mechanical engineering from Purdue University.
Bhaskar Chaudhuri

Bhaskar Chaudhuri,具有20多年的制药管理和研发经验。2011年6月起,他担任Frazier Healthcare的经营合伙人。他担任Valeant Pharmaceuticals International的总裁直至2010年9月。2009年1月加入Valeant前,他担任Dow的总裁和首席执行官7年,2003-2008年担任其董事会成员,直至Dow被Laleant收购。此前,他担任Mylan Laboratories的分公司Bertek Pharmaceuticals的科学事务执行副总裁。在Bertek任职前,他担任Mylan Laboratories的皮肤病部门总经理。随着Mylan并购Penederm, Inc.,他加入Mylan,1992-1998年担任多个高级职务,任至研发部副总裁。他获有University of Louisiana的生理药学博士学位,印度的工业药学硕士学位和药理学学士学位。


Bhaskar Chaudhuri has served as a member of our board of directors since December 2019. Since June 2011 he has been the Operating Partner at Frazier Healthcare Ventures. Prior to that time, Dr. Chaudhuri served as President of Valeant Pharmaceuticals International, Inc. from January 2009 to September 2010. Prior to joining Valeant, Dr. Chaudhuri served for seven years as President and Chief Executive Officer of Dow Pharmaceutical Sciences, Inc. and as a member of its board of directors from 2003 to 2008 at which time Dow was acquired by Valeant. Prior to that, Dr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, Inc., a subsidiary of Mylan N.V., from 1998 to 2000. Prior to his positions at Bertek, Dr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan. Dr. Chaudhuri joined Mylan through the acquisition of Penederm, Inc., where he worked from 1992 to 1998 in a number of senior positions before becoming the Vice President of Research and Development. Dr. Chaudhuri currently serves on the boards of directors of Arcutis Biotherapeutics, Inc., since June 2016 Teligent Pharmaceuticals, Inc. since November 2010 and Vyome Biosciences, Ltd. since June 2015. He also serves on the Advisory Board of the Berman Institute of John Hopkins University. Dr. Chaudhuri holds a Bachelor of Science degree in Pharmacy and an M.S. in Industrial Pharmacy from Jadavpur University and a Ph.D. in Pharmaceutics form the University of Louisiana.
Bhaskar Chaudhuri,具有20多年的制药管理和研发经验。2011年6月起,他担任Frazier Healthcare的经营合伙人。他担任Valeant Pharmaceuticals International的总裁直至2010年9月。2009年1月加入Valeant前,他担任Dow的总裁和首席执行官7年,2003-2008年担任其董事会成员,直至Dow被Laleant收购。此前,他担任Mylan Laboratories的分公司Bertek Pharmaceuticals的科学事务执行副总裁。在Bertek任职前,他担任Mylan Laboratories的皮肤病部门总经理。随着Mylan并购Penederm, Inc.,他加入Mylan,1992-1998年担任多个高级职务,任至研发部副总裁。他获有University of Louisiana的生理药学博士学位,印度的工业药学硕士学位和药理学学士学位。
Bhaskar Chaudhuri has served as a member of our board of directors since December 2019. Since June 2011 he has been the Operating Partner at Frazier Healthcare Ventures. Prior to that time, Dr. Chaudhuri served as President of Valeant Pharmaceuticals International, Inc. from January 2009 to September 2010. Prior to joining Valeant, Dr. Chaudhuri served for seven years as President and Chief Executive Officer of Dow Pharmaceutical Sciences, Inc. and as a member of its board of directors from 2003 to 2008 at which time Dow was acquired by Valeant. Prior to that, Dr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, Inc., a subsidiary of Mylan N.V., from 1998 to 2000. Prior to his positions at Bertek, Dr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan. Dr. Chaudhuri joined Mylan through the acquisition of Penederm, Inc., where he worked from 1992 to 1998 in a number of senior positions before becoming the Vice President of Research and Development. Dr. Chaudhuri currently serves on the boards of directors of Arcutis Biotherapeutics, Inc., since June 2016 Teligent Pharmaceuticals, Inc. since November 2010 and Vyome Biosciences, Ltd. since June 2015. He also serves on the Advisory Board of the Berman Institute of John Hopkins University. Dr. Chaudhuri holds a Bachelor of Science degree in Pharmacy and an M.S. in Industrial Pharmacy from Jadavpur University and a Ph.D. in Pharmaceutics form the University of Louisiana.

高管简历

中英对照 |  中文 |  英文
Bobak Azamian
暂无中文简介

Bobak Azamian is our co-founder and has served as our President since our inception, as our Chief Executive Officer since September 2018 and as a member of our board of directors since December 2016. From June 2012 to September 2018 Dr. Azamian co-founded and served as Chief Executive Officer, President, and Chief Medical Officer of Metavention, Inc., a company focused on treatment of diabetes and other metabolic diseases. Since September 2016 Dr. Azamian has also served as co-founder, co-Chairman and Chief Executive Officer of Vibrato Medical, Inc., a medical device company developing wearable treatments for peripheral arterial disease. Dr. Azamian previously served as an Entrepreneur in Residence at Versant Ventures from 2011 to 2013 and as a consultant and Senior Associate at Third Rock Ventures from 2007 to 2011 both venture capital firms focused on investing in early stage healthcare companies, and earlier served as a consultant at Amgen. He also completed residency in internal medicine and served as an attending hospitalist at Brigham and Women’s Hospital from 2006 to 2011. Dr. Azamian received a B.A. in Biophysics from Rice University, a Doctor of Philosophy Chemistry from University of Oxford and a Doctor of Medicine from Harvard Medical School.
暂无中文简介
Bobak Azamian is our co-founder and has served as our President since our inception, as our Chief Executive Officer since September 2018 and as a member of our board of directors since December 2016. From June 2012 to September 2018 Dr. Azamian co-founded and served as Chief Executive Officer, President, and Chief Medical Officer of Metavention, Inc., a company focused on treatment of diabetes and other metabolic diseases. Since September 2016 Dr. Azamian has also served as co-founder, co-Chairman and Chief Executive Officer of Vibrato Medical, Inc., a medical device company developing wearable treatments for peripheral arterial disease. Dr. Azamian previously served as an Entrepreneur in Residence at Versant Ventures from 2011 to 2013 and as a consultant and Senior Associate at Third Rock Ventures from 2007 to 2011 both venture capital firms focused on investing in early stage healthcare companies, and earlier served as a consultant at Amgen. He also completed residency in internal medicine and served as an attending hospitalist at Brigham and Women’s Hospital from 2006 to 2011. Dr. Azamian received a B.A. in Biophysics from Rice University, a Doctor of Philosophy Chemistry from University of Oxford and a Doctor of Medicine from Harvard Medical School.
Seshadri Neervannan
暂无中文简介

Seshadri Neervannan has served as our Chief Operating Officer since July 2020. Dr. Neervannan previously served as Senior Vice President of Global Pharmaceutical Development, from March 2015 to July 2020 at Allergan, and Vice President, Pharmaceutical Development, from January 2007 to February 2015 at Allergan Inc., a global pharmaceutical company. Prior to Allergan he was Director of Pharmaceutics R&D, at Amgen Inc., a biotechnology company, from February 1999 to January 2007. From November 1994 to February 1999 Dr. Neervannan was Sr. Research Investigator at Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Neervannan received a B.S. in Pharmacy with Honors from Birla Institute of Technology & Science, Pilani, India, and a Ph.D. (with Honors) in Pharmaceutical Chemistry from the University of Kansas, Lawrence, KS.
暂无中文简介
Seshadri Neervannan has served as our Chief Operating Officer since July 2020. Dr. Neervannan previously served as Senior Vice President of Global Pharmaceutical Development, from March 2015 to July 2020 at Allergan, and Vice President, Pharmaceutical Development, from January 2007 to February 2015 at Allergan Inc., a global pharmaceutical company. Prior to Allergan he was Director of Pharmaceutics R&D, at Amgen Inc., a biotechnology company, from February 1999 to January 2007. From November 1994 to February 1999 Dr. Neervannan was Sr. Research Investigator at Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Neervannan received a B.S. in Pharmacy with Honors from Birla Institute of Technology & Science, Pilani, India, and a Ph.D. (with Honors) in Pharmaceutical Chemistry from the University of Kansas, Lawrence, KS.
Aziz Mottiwala
暂无中文简介

Aziz Mottiwala has served as our Chief Commercial Officer since August 2020. Mr. Mottiwala has served on the board of directors of OneOC, a non-profit organization based in Orange County, California since March 2018. Mr. Mottiwala previously served as Chief Commercial Officer of Opiant Pharmaceutical, Inc., or Opiant, a publicly-traded pharmaceutical company specializing in medicines for the treatment of addictions and drug overdose from September 2019 to August 2020. Prior to Opiant, Mr. Mottiwala served as Senior Vice President of Sales and Marketing and Head of Commercial at Avanir Pharmaceuticals, Inc., or Avanir, a pharmaceutical company specializing in medicines to treat nervous system disorders from July 2017 to September 2019. Prior to Avanir, Mr. Mottiwala spent over ten years at Allergan, a global pharmaceutical company, in various roles from December 2006 to July 2017 most recently as Vice President of Marketing for Allergan’s eye car portfolio from January 2014 to July 2017. Mr. Mottiwala holds a Bachelor of Science degree in Biochemistry from the University of California San Diego and an MBA in Marketing and Finance from the Marshall School of Business at the University of Southern California.
暂无中文简介
Aziz Mottiwala has served as our Chief Commercial Officer since August 2020. Mr. Mottiwala has served on the board of directors of OneOC, a non-profit organization based in Orange County, California since March 2018. Mr. Mottiwala previously served as Chief Commercial Officer of Opiant Pharmaceutical, Inc., or Opiant, a publicly-traded pharmaceutical company specializing in medicines for the treatment of addictions and drug overdose from September 2019 to August 2020. Prior to Opiant, Mr. Mottiwala served as Senior Vice President of Sales and Marketing and Head of Commercial at Avanir Pharmaceuticals, Inc., or Avanir, a pharmaceutical company specializing in medicines to treat nervous system disorders from July 2017 to September 2019. Prior to Avanir, Mr. Mottiwala spent over ten years at Allergan, a global pharmaceutical company, in various roles from December 2006 to July 2017 most recently as Vice President of Marketing for Allergan’s eye car portfolio from January 2014 to July 2017. Mr. Mottiwala holds a Bachelor of Science degree in Biochemistry from the University of California San Diego and an MBA in Marketing and Finance from the Marshall School of Business at the University of Southern California.
Mark Holdbrook
暂无中文简介

Mark Holdbrook has served as our Vice President of Clinical Affairs since November 2018. Prior to this Mr. Holdbrook was an independent consultant from October 2017 to November 2018 and served as Senior/Executive Director for Oculeve, which was acquired by Allergan, from May 2014 to October 2017. Mr. Holdbrook received a B.A. from the University of California at San Diego.
暂无中文简介
Mark Holdbrook has served as our Vice President of Clinical Affairs since November 2018. Prior to this Mr. Holdbrook was an independent consultant from October 2017 to November 2018 and served as Senior/Executive Director for Oculeve, which was acquired by Allergan, from May 2014 to October 2017. Mr. Holdbrook received a B.A. from the University of California at San Diego.
Leo M. Greenstein

Leo M. Greenstein于2011年5月加入我司,担任我司财务部副总裁与公司财务总监。他拥有超过14年的财务与会计工作经验。加入我司前,他担任科莱恩公司(Clarient, Inc.)的财务部与美国证交会报告部高级总监,这是一家癌症治疗的分子诊断公司。在该职务上,他负责管理科莱恩公司的美国证交会(SEC)与纳斯达克(NASDAQ)合规、技术会计、税务合规、法律与业务运营以及风险管理监管的各个方面。他还协助开展债务与股权的资本募集活动,并完成了几项收购与剥离。加入科莱恩公司以前,他担任防卫科技公司(Safeguard Scientifics Inc.)的多数股东的财务总管助理,这是一家位于费城地区的公开注册的风险投资公司,其为生命科学与技术公司提供成长资本与管理支持。Greenstein先生于1999年在宾夕法尼亚州格兰赛德市的阿卡迪亚大学(Arcadia University)获得会计学文学学士学位,他在那里于2008年和2009年还担任会计学兼职教授。他在费城开启其职业生涯,从事公共会计达8年,晋升至普华永道会计师事务所(PricewaterhouseCoopers LLP)的审计经理的职位。从事公共会计时,他在天普大学(Temple University)的比斯利法学院获得法学学位。Greenstein先生是加利福尼亚州的执业注册会计师,他已成功通过加利福尼亚州律师协会(California Bar)的考试。


Leo M. Greenstein has served as our Chief Financial Officer since April 2020. Mr. Greenstein previously served as Senior Vice President of Finance and Corporate Controller at Spectrum Pharmaceuticals, Inc., a publicly-traded oncology pharmaceutical company from September 2013 until April 2020. Prior to Spectrum Pharmaceuticals, Mr. Greenstein served as Vice President of Finance and Corporate Controller at Endologix, Inc., a publicly-traded medical device company, from May 2011 to September 2013 and Senior Director of Finance and SEC Reporting at Clarient, Inc., a then publicly-traded advanced oncology diagnostics services company, from June 2007 to April 2011 inclusive of his finance role with its then-majority shareholder. Mr. Greenstein spent eight years in Big-4 Public Accounting, beginning with Arthur Andersen LLP in September 1999 and ending with PriceWaterhouseCoopers LLP in June 2007. Mr. Greenstein received a B.A. in Accounting from Arcadia University and Juris Doctorate from the Temple University Beasley School of Law. He is an active attorney and member of the State Bar of California and is an active Certified Public Accountant in California.
Leo M. Greenstein于2011年5月加入我司,担任我司财务部副总裁与公司财务总监。他拥有超过14年的财务与会计工作经验。加入我司前,他担任科莱恩公司(Clarient, Inc.)的财务部与美国证交会报告部高级总监,这是一家癌症治疗的分子诊断公司。在该职务上,他负责管理科莱恩公司的美国证交会(SEC)与纳斯达克(NASDAQ)合规、技术会计、税务合规、法律与业务运营以及风险管理监管的各个方面。他还协助开展债务与股权的资本募集活动,并完成了几项收购与剥离。加入科莱恩公司以前,他担任防卫科技公司(Safeguard Scientifics Inc.)的多数股东的财务总管助理,这是一家位于费城地区的公开注册的风险投资公司,其为生命科学与技术公司提供成长资本与管理支持。Greenstein先生于1999年在宾夕法尼亚州格兰赛德市的阿卡迪亚大学(Arcadia University)获得会计学文学学士学位,他在那里于2008年和2009年还担任会计学兼职教授。他在费城开启其职业生涯,从事公共会计达8年,晋升至普华永道会计师事务所(PricewaterhouseCoopers LLP)的审计经理的职位。从事公共会计时,他在天普大学(Temple University)的比斯利法学院获得法学学位。Greenstein先生是加利福尼亚州的执业注册会计师,他已成功通过加利福尼亚州律师协会(California Bar)的考试。
Leo M. Greenstein has served as our Chief Financial Officer since April 2020. Mr. Greenstein previously served as Senior Vice President of Finance and Corporate Controller at Spectrum Pharmaceuticals, Inc., a publicly-traded oncology pharmaceutical company from September 2013 until April 2020. Prior to Spectrum Pharmaceuticals, Mr. Greenstein served as Vice President of Finance and Corporate Controller at Endologix, Inc., a publicly-traded medical device company, from May 2011 to September 2013 and Senior Director of Finance and SEC Reporting at Clarient, Inc., a then publicly-traded advanced oncology diagnostics services company, from June 2007 to April 2011 inclusive of his finance role with its then-majority shareholder. Mr. Greenstein spent eight years in Big-4 Public Accounting, beginning with Arthur Andersen LLP in September 1999 and ending with PriceWaterhouseCoopers LLP in June 2007. Mr. Greenstein received a B.A. in Accounting from Arcadia University and Juris Doctorate from the Temple University Beasley School of Law. He is an active attorney and member of the State Bar of California and is an active Certified Public Accountant in California.